LBTSF - Athenex gains 10% on FDA approval of Klisyri in pre-cancerous skin lesion

Athenex (ATNX) jumps 10% premarket on after FDA approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis ((AK)) on the face or scalp.Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall (LBTSF) in the U.S. during Q1 2021. In addition to the partnership with Almirall, Athenex has partnered with PharmaEssentia in Taiwan and with Xiangxue Pharmaceuticals in China, Hong Kong, and Macau for AK.Actinic keratosis is a pre-cancerous skin lesion. If left untreated, 10-15% of AK lesions will develop into skin cancers.

For further details see:

Athenex gains 10% on FDA approval of Klisyri in pre-cancerous skin lesion